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We reported recently that the inflammatory cytokine tumour necrosis factor a (TNF-a) can upregulate integrin expression, cell
attachment and invasion of cells through fibronectin in a human melanoma cell line (HBL). Furthermore, the actions of TNF-a were
suppressed by the addition of an anti-inflammatory peptide a-melanocyte-stimulating hormone (a-MSH). In the current study, we
extend this work investigating to what extent TNF-a might stimulate melanoma invasion by promoting cell migration and whether a-
MSH is also inhibitory. Two human melanoma cell lines were examined in vitro (HBL and C8161) using a scratch migration assay.
Analysis using either time-lapse video microscopy or imaging software analysis of migrating ‘fronts’ of cells revealed that C8161 cells
migrated more rapidly than HBL cells. However, when cells were stimulated with TNF-a both cell types responded with a significant
increase in migration distance over a 16–26 h incubation time. a-Melanocyte-stimulating hormone had an inhibitory effect on TNF-a-
stimulated migration for HBL cells, completely blocking migration at 109 M. In contrast, C8161 cells did not respond to a-MSH (as
these cells have a loss-of-function melanocortin-1 receptor). However, stable transfection of C8161 cells with the wild-type
melanocortin-1 receptor produced cells whose migration was significantly inhibited by a-MSH. In addition, the use of a neutralising
antibody to the b1-integrin subunit significantly reduced migration in both cell types. This data therefore supports an inflammatory
environment promoting melanoma cell migration, and in addition shows that a-MSH can inhibit inflammatory stimulated migration.
The data also support a fundamental role of the b1-integrin receptor in melanoma cell migration.
British Journal of Cancer (2004) 90, 1457–1463. doi:10.1038/sj.bjc.6601698 www.bjcancer.com
Published online 2 March 2004
& 2004 Cancer Research UK
Keywords: melanoma; a-MSH; inflammation; integrin; melanocortin























































Despite public education on the risk of sunshine and associated
UV light exposure and the increasing number of dermatology
screening clinics, the incidence of melanoma continues to rise
(Oliveria et al, 2001; Lang, 2002). Although treatment of early stage
tumours is largely successful, nodal metastasis is associated with
70% mortality after 10 years if multiple lymph nodes are involved
(Soong et al, 1992). Of particular concern are clinical observations
that following excision of a primary malignant melanoma
reoccurrence can arise at the wound site after a number of
months. In support of this observation, animal studies demon-
strate that a wound-healing environment can enhance local
tumour growth and accelerate the development of distant
melanoma metastases (Bogden et al, 1997; Hofer et al, 1998).
One of the very first events in a normal healing wound is an
acute inflammatory response. Inflammation is needed to combat
possible infection but also to stimulate cellular proliferation
necessary for tissue repair. However, it is possible that the same
early inflammatory signals may also promote malignant melanoma
invasion and metastasis. The strongest evidence implicating an
inflammatory response in the development of metastases is from
colorectal cancer, where anti-inflammatory drug use is associated
with a lower incidence of tumour recurrence (Benamouzig et al,
2001). A study of oral indomethacin and ranitidine in patients with
advanced melanoma reported a partial response in two out of 17
patients, with reduction of metastatic tumour mass (Mertens and
Lohmann, 1996). Indomethacin has been found to inhibit
metastases and influence the cytotoxic activity of natural killer
cells both in vitro and in animal models (Bigda and Mysliwski,
1998), and also induces apoptosis in oesophageal carcinoma cells
(Aggarwal et al, 2000) and prostatic carcinoma cell lines (Andrews
et al, 2002). In support of these observations, salicylic acid (a
closely related anti-inflammatory compound) is reported to inhibit
breast cancer cell growth (Sotiriou et al, 1999).
In common with other malignancies, an inflammatory stress,
such as sublethal laser radiation (Zhu et al, 1997, 1999), can
promote metastasis of melanoma (Giavazzi et al, 1990; Dekker et al,
1994; Link et al, 1999). Changes in the expression of cellular
adhesion molecules (Hynes, 1992; Natali et al, 1993; Danen et al,
1995; Stuiver and O’Toole, 1995) and matrix metalloproteinase
activity (Hojo et al, 2002) are strongly associated with an increase
in melanoma phenotype and invasion. Of particular note is that
integrin and adhesion molecule expression can be directly
upregulated by proinflammatory cytokines within the local cellular
environment (Creyghton et al, 1995).
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In support of the above, we have recently shown that integrin
expression, cell attachment and invasion through fibronectin are
upregulated by the proinflammatory cytokine TNF-a and opposed
by a-MSH (Zhu et al, 2002) in a human cutaneous melanoma cell
line (HBL). We also found TNF-a to cause a modest increase in
proteolytic activity, which could be blocked effectively using a2
macroglobulin (Katerinaki et al, 2003), but with no concomitant
increase in matrix metalloproteinase 2 or 9 activation or
expression. However, the above studies did not consider whether
melanoma invasion through fibronectin was attributable specifi-
cally to an increase in cell migration or to an increase in invasion.
The use of in vitro scratch assays has previously enabled study of
cellular migration alone (e.g. inhibition of neuroblastoma migra-
tion by retinoic acid (Voigt and Zintl, 2003) and the role of a-2
integrin expression in ovarian carcinoma cell migration (Koke-
nyesi et al, 2003)). Therefore, in the present study, we have
investigated whether the inflammatory cytokine TNF-a acts by
promoting melanoma cell migration in vitro, using this approach.
In addition, we have studied whether a-MSH has an inhibitory
potential on the role of TNF-a. We also considered the
requirement of melanoma cells to express a wild-type melano-
cortin receptor for a-MSH signalling and whether the b1 integrin
subunit is a fundamental requirement for migration of melanoma
cells.
MATERIALS AND METHODS
Human cutaneous melanoma cell culture
The human HBL cutaneous melanoma cell line was originally
established in the laboratory of Professor GE Ghanem, University
of Brussels, Belgium from a lymph node metastasis of a nodular
malignant melanoma (Ghanem et al, 1988). Cells were cultured in
Ham’s F10 medium (Gibco, Paisley, Scotland) supplemented with
5% (v v1) foetal calf serum (FCS), 5% (v v1) neonatal calf serum
(NCS) (Sigma, Poole, Dorset, UK), 2 mM L-glutamine, 100 U ml1
penicillin and 100 mg ml1 streptomycin sulphate. The human
C8161 melanoma line was established from an abdominal wall
metastasis from a menopausal woman with recurrent melanoma
(kindly donated by Professor F Meyskens, University of California,
Irvine, USA, via Professor M Edwards University of Glasgow, UK).
Cells were cultured in Eagle’s modified essential medium (EMEM)
supplemented with 10% (v v1) FCS, 2 mM L-glutamine, 100 U ml1
penicillin and 100 mg ml1 streptomycin sulphate, 1.2 mg ml1
amphotericin B, 1.5% (v v1) (of a 100 stock solution) vitamin
concentrate, 1 mM sodium pyruvate, 1% (v v1) nonessential
amino acids (NEA) and 0.187% (w v1) sodium hydrogen
carbonate (Sigma, Poole, Dorset, UK). Cells were incubated at
371C in a humidified 5% carbon dioxide/95% air environment
under standard conditions and passaged prior to confluence using
0.02% (w v1) ethylenediamine tetraacetic acid (EDTA). Cells were
used between passages 30– 35 for experimentation and were grown
to 60% confluence prior to incubation with a-MSH (1012 –106 M;
Sigma, Poole, Dorset, UK), TNF-a (100 –750 U ml1; Sigma, Poole,
Dorset, UK) or a coincubation of the two as detailed previously
(Hedley et al, 1998; Haycock et al, 1999a b; 2000). For experiments
using a neutralising antibody to the b1 integrin subunit, cells were
grown under standard conditions to 60% confluence, then
incubated with an anti-b1 integrin neutralising antibody
(4mg ml1) for 24 h (Upstate Biotechnology, Lake Placid, NY,
USA).
Generation of a C8161 human melanoma line stably
transfected with the melanocortin-1 receptor
A stable C8161 melanoma cell line expressing functional MC-1
receptor was isolated by transfecting C8161 cells with vector pRc/
CMV carrying MC-1 receptor cDNA (kindly donated by Professor
JES Wikberg, University of Uppsala, Sweden). Briefly, cells were
plated in 100 mm dishes in complete EMEM media. After growth to
approximately 70% confluence, cells were transfected with 15 mg of
pRC/CMV/MC-1 DNA using Tfxt-50 Reagent, according to the
manufacturer’s (Promega, UK) protocol (together with a b-
galactosidase reporter construct). Individual transfectants were
isolated and cloned by limiting dilution following growth in
complete EMEM media containing 500mg ml1 geneticin (G-418).
Transfection efficiency was confirmed via the b-galactosidase-
cotransfected reporter gene.
Assessment of melanoma cell migration using a scratch
migration assay: analysis by continuous time-lapse video
microscopy
A modified ‘scratch’ migration assay was used for the assessment
of the migration of melanoma cells, previously described by Cha
et al (1996) for studying keratinocyte cell migration. Human
melanoma cell line and C8161 cells (which have a doubling time of
24 and 20 h, respectively) were cultured in two 25 cm2 sample
flasks until 90% confluent, and incubated with TNF-a or a-MSH
(alone or in combination) for 4–32 h. A migration gap of
approximately 1 mm was then created by introducing a ‘scratch’
to the adherent layer of cultured cells using a sterile Gilson 1 ml
pipette tip. The scratch was administered by hand using a
sufficiently applied degree of pressure to remove adherent cells
from the polystyrene substrate, but not enough to cause a physical
damage to the polystyrene surface. The repeated nature of this task
with practice resulted in a cell-free gap of 1.070.12 mm (n¼ 3)
between two adjoining areas of melanoma cells at 90% confluence.
At this point, half of the culture medium was removed and
replaced with fresh medium to reduce the number of cells
introduced into suspension reattaching to the cell-free zone during
experimentation. Flasks were then incubated in a 95% air/5% CO2
environment for 1 h before being tightly sealed to maintain the
above environment during experimentation. Cultures were filmed
by video synchronisation (EOS Electronics AV Ltd, UK) using a
Leitz DM-IRB inverted microscope (Leica UK Ltd) at 371C.
Migration of the melanoma cells from the two regions of 90%
adherent culture density in to the cell-free zone was observed over
a 24 h time period and recorded by video microscopy (one frame
being recorded every 2 min). Films were then analysed and the
number of cells migrating into the cell-free zone created by the
scratch of area 1.070.12 mm in width by 2.0 mm in length
(corresponding exactly with the microscope optic field-of-view)
were counted manually at intervals of 4, 8, 12, 16, 20 and 24 h.
Assessment of melanoma cell migration using a scratch
migration assay: analysis by time-interval optical imaging
microscopy
The above method was developed further for enabling multiple
samples to be analysed during a single experiment (as opposed to
two-sample measurements, which proved to be highly accurate but
unsuitable for simultaneous study). Cells were cultured as above,
but in 24-well plates of 1.5 cm diameter. Prior to cell seeding, the
underside of the tissue culture well was marked into six quadrants
with an indelible pen. Two linear ‘scratches’ were placed across the
adherent monolayer creating cell-free zones as above, ensuring
that each scratch traversed all six quadrants in each well. Scratches
were examined under a microscope and three were selected for
experimentation on the basis of uniformity of area. Micrograph
images of the scratch were taken at time¼ 0 min and then TNF-a
or a-MSH (alone or in combination) was added as required. The
width of the cell-free zone was then measured at 0, 4, 8 and 24 h
after cytokine or peptide addition using Openlab v3.0.2, image
analysis software (Improvision, Coventry, UK) and the migrating
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front of cells was calculated accordingly as a measure of migration
speed.
Statistics
Mean and standard error of the mean values were used for
establishing statistical significance between control and cytokine/
peptide-incubated samples using Students’ paired t-test. Signifi-
cance was taken when Pp0.05. Data are expressed in the Results
section as a percentage of control.
RESULTS
Migration of cultured HBL and C8161 human melanoma
cells
Figure 1 shows phase-contrast optical micrographs of the two
cultured melanoma cell lines (C8161 and HBL) at 0, 8 and 24 h
after creation of a cell-free zone using the ‘scratch’ technique. It
can be seen that at time¼ 0, two distinct regions are observed
where melanoma cells at 90% confluence are separated by a cell-
free zone of approximately a 1 mm width, created by the pipette tip
scratch. A continuous rapid and random movement was observed
for all cells within minutes, but a resultant movement of a
melanoma cell migration front was clearly evident over 24 h, where
a highly confluent (90–100%) monolayer region gradually
migrated into the cell-free ‘scratch’ region. The C8161 melanoma
cells migrated more rapidly than the HBL cells over the 24-h time
period, due to a faster migration speed (Figures 1 and 2A). It is
important to note that the C8161 line has a 20-h doubling time and
the HBL line a 24-h doubling time. However, from visual analysis
of the time-lapse microscopy, it is clearly evident that occupation
of the gap is predominantly via migration, rather than a simple
Figure 1 Cultured human HBL and C8161 melanoma cells were
investigated for potential to migrate into a cell-free scratch region. This is
illustrated for HBL melanoma cells cultured for: (A) 0 h; (B) 8 h and (C)
24 h after administration of the scratch, and similarly for cultured C8161
melanoma cells at: (D) 0 h; (E) 8 h and (F) and 24 h after a scratch was
made. Bar¼ 0.5 mm.
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Figure 2 (A) Distance migrated of cultured HBL (&) and C8161 (’)
melanoma cells over 24 h using the scratch assay technique. (B) Time
course of TNF-a (300 U ml1) action on HBL melanoma cell migration.
Key: (m) no TNF-a; (n) 4 h preincubation with TNF-a; (’) 8 h
preincubation with TNF-a and (&) 24 h preincubation with TNF-a. (C)
The effect of TNF-a (300 U ml1) on migration of C8161 melanoma cells.
Key: (E) no TNF-a and (’) cells pretreated with TNF-a for 24 h prior to
administration of scratch. Values shown are mean7s.e.m. (n¼ 3).
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doubling of the cells (data present as a separate avi file). A
comparison of the two analytical techniques for assessing
migration revealed that similar data was obtained irrespective of
whether time-lapse video microscopy or time-interval image
analysis was used. Therefore, subsequent experiments were
conducted using time-interval image analysis. Data is described
as the migration distance attained, measured by a reduction in the
width of the initial scratch.
Tumour necrosis factor a increases migration of HBL and
C8161 melanoma cells
Preincubation of HBL and C8161 melanoma cells with TNF-a
(300 U ml1) prior to introducing a ‘scratch’ resulted in an increase
in the rate of migration of both melanoma cell lines (Figure 2). For
HBL cells, the greatest increase in migration speed was observed
when cells were preincubated for 24 h (Figure 2B). Preincubation
for 4 h had no effect on migration speed, and preincubation for 8 h
revealed a faster migration than control cells, but not as fast as a
24 h incubation (Figure 2B). A similar time course of action of
TNF-a preincubation was observed with C8161 cells (Figure 2C).
However, as these cells displayed a faster basal migration speed
compared to HBL cells, we found that after 24 h no difference was
observed between TNF-a-stimulated and unstimulated cells. This
was due to control cells migrating completely in the assay system.
The greatest increase in migration speed for HBL cells was
observed when TNF-a at 300 U ml1 was used with a preincubation
time of 24 h (Figure 3A). Time-lapse video microscopy data for
TNF-a-stimulated C8161 cells is present as an avi file.
a-Melanocyte-stimulating hormone inhibits TNF-a-
stimulated migration of HBL melanoma cells but not
C8161 melanoma cells
The above experiments investigating the preincubation time and
the concentrations of TNF-a-stimulating melanoma cell migration
enabled us to select a 24 h preincubation of TNF-a at 300 U ml1
and a migration time point of 24 h for investigating the action of a-
MSH on melanoma migration. a-Melanocyte-stimulating hormone
at a concentration range of 1012 – 109 M had a significant
inhibitory effect on HBL cell migration, whereas higher concen-
trations of 108 –106 M did not (Figure 3B). Figure 4 compares the
response to a-MSH (109 M) on unstimulated and TNF-a
(300 U ml1)-stimulated HBL and C8161 cells. In HBL cells
(Figure 4A), TNF-a (300 U ml1) significantly increased cell
migration (Po0.001), while a-MSH (109 M) significantly de-
creased HBL migration alone (Po0.05) and in combination with
TNF-a (Po0.01). In contrast, Figure 4B illustrates that while TNF-
a (300 U ml1) alone significantly increased migration of C8161
cells (Po0.001), a-MSH failed to influence unstimulated or TNF-a-
stimulated migration for these cells. However, when C8161 cells
were transfected with the wild-type melanocortin-1 receptor
(Figure 4C), a-MSH at 109 M significantly reduced unstimulated
C8161 migration (Po0.05) and also completely blocked the
response of the transfected cells to TNF-a (Po0.01). The
procedure of transfecting C8161 cells was not found to influence
the absolute rate of migration significantly compared with
untransfected cells, as can be seen by comparing both control
and TNF-a-stimulated and migration rates between these two
populations of cells (Figure 4B and C).
Neutralising antibody to b1 integrin inhibits the migration
of HBL and C8161 melanoma cells
The addition of a neutralising antibody to melanoma cells was
observed to significantly inhibit their ability to migrate over a 24-h
time period. Data for the C8161 cells are given in Figure 5A and for
HBL cell in Figure 5B. Addition of neutralising antibody to the
integrin b1 subunit reduced the rate of migration of HBL and
C8161 cells by 4673.2 and 4872.8%, respectively, 24 h after the
formation of a scratch. Time-lapse video microscopy data for
C8161 cells plus anti-integrin b1 is present as an avi file. Control
experiments using an isotype IgG control antibody did not
significantly affect the migration speed of either cell type.
DISCUSSION
The aim of this study was to investigate the effect of the
proinflammatory cytokine TNF-a and the anti-inflammatory
peptide a-MSH on melanoma cell migration. This work extends
recently published findings from our group describing TNF-a
increased melanoma cell attachment, invasion through fibronectin
and expression of integrins a3, a4 and b1 (Zhu et al, 2002). The
present study demonstrates that melanoma cell migration is
increased by TNF-a in two melanoma cell lines. We also show that
the HBL cell line (which has a wild-type melanocortin-1 receptor)
responds to a-MSH with a reduction in TNF-a-stimulated
migration. In contrast, the C8161 cell line (which has a
polymorphic loss of function of the MC-1 receptor) does not
respond to the action of a-MSH. However, when these cells are
stably transfected with the wild-type MC-1 receptor, it restores a-
MSH function, such that the cells then responded with a significant
reduction in TNF-a-stimulated migration.
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Figure 3 (A) The dose-dependant effect of TNF-a on the migration of
HBL melanoma cells over a 24 h time period (cells were preincubated with
TNF-a for 24 h prior to scratch administration). (B) The dose-dependant
effect of a-MSH on inhibiting the migration of HBL melanoma cells
stimulated with TNF-a (300 U ml1) over 24 h. Values shown are
mean7s.e.m. (n¼ 3).
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Proinflammatory cytokines TNF-a and IL-1a can upregulate a4,
a5 and a6-melanoma integrin expression, with an associated
increase in migration on fibronectin (Giavazzi et al, 1990; Dekker
et al, 1994). In support of this, we have reported previously that
human HBL melanoma cells in culture respond to TNF-a with an
upregulation of a3, a4 and b1 integrin expression (Zhu et al, 2002).
This was associated with an increase in fibronectin invasion. In
addition, the anti-inflammatory peptide a-MSH was effective at
decreasing HBL cell attachment and invasion (Zhu et al, 2002).
The in vivo invasion of melanoma cells probably involves two
components – an increase in the rate of cellular migration and an
increase in the proteolytic activity necessary to degrade the
extracellular matrix. The current in vitro study investigated the
extent to which the stimulatory action of TNF-a on melanoma
invasion is explained by an action on cellular migration rather
than on proteolytic degradation of the surrounding matrix. In vitro
and in vivo invasion may involve both increased migration and
increased proteolytic breakdown of the matrix. Thus, we recently
found that while TNF-a did not cause an obvious upregulation of
proteolytic activity in HBL cells, the introduction of a broad-
spectrum protease inhibitor (a2 macroglobulin) was able to block
TNF-a-stimulated cell invasion and cell migration (Katerinaki et al,
2003). In the current study, we compared two methods for
measuring cell migration, both based on introducing a ‘scratch’ to
a cultured monolayer of cells (adapted from a method previously
reported for keratinocytes (Cha et al, 1996)). One method used
time-lapse video microscopy and counted the number of cells
entering a defined cell-free area in a given period of time. The
other relied on a computer software image analysis measurement
of the decreasing width of the remaining scratch as the melanoma
cell ‘fronts’ advanced. The video microscopy approach had a
technical advantage of enabling a complete experiment to be run
without physical disturbance (as incubator conditions were
present during recording). This was useful for experiments
conducted using cells that have a relatively weak affinity for the
surface substratum (such as the HBL melanoma cell line). A
second major advantage of this method is that it allows the
continuous viewing of all cells, enabling one to look at whether
changes in migration velocity were attributable equally to all cells,
to a subpopulation of cells or was due predominantly to the rate of
cell doubling (as opposed to migration). This did not appear to be
the case in these experiments. However, cell migration using this
method was quantified by manually counting cells (which is a
tedious and time consuming process). Another major experimental
limitation was that we were only able to process two samples at a
time, limiting the number of variables investigated in any one
experiment.
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Figure 4 (A) The comparative effect of a-MSH (109 M) on control
unstimulated and TNF-a-stimulated (300 U ml1) migration of cultured
HBL melanoma cells, (B) C8161 melanoma cells and (C) C8161
melanoma cells stably transfected with the melanocortin-1 receptor.
Values shown are mean7s.e.m. (n¼ 3). *Po0.05, **Po0.01,
***Po0.001.
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Figure 5 (A) The effect of a neutralising antibody to the b1 integrin
subunit on migration of C8161 melanoma cells over 24 h following
administration of a scratch. Key: (K) control, no antibody and (&) anti-b1
integrin antibody (4 mg ml1). (B) Effect of neutralising antibody to b1
integrin subunit on migration of HBL melanoma cells at 24 h after scratch.
Values shown are mean7s.e.m. (n¼ 3). *Po0.05, **Po0.01,
***Po0.001.
Inflammation and melanoma
N Zhu et al
1461
British Journal of Cancer (2004) 90(7), 1457 – 1463& 2004 Cancer Research UK
E
x
p
e
ri
m
e
n
ta
l
T
h
e
ra
p
e
u
ti
c
s
In contrast, the image analysis method of the multiple scratches
per well allowed replicate data points and dose–response
experiments to be undertaken. It did require cultured cells to be
physically moved between tissue culture incubator and microscope
for assessment, thus care had to be taken when handling
weakly adherent cells. This problem is minimised by avoiding
complete medium changes (which can detach all attached cells)
and careful physical handling. Both methods of assessment
relied upon scratches (using a polystyrene disposable pipette tip)
that needed to be as reproducible as possible in width. In practice,
we found that it was feasible to produce scratches of a reproducible
width by conducting sufficient replicates. These could be run
so that irregular scratches were identified and discarded
prior to entry into experiments. Similar approaches using this
methodology have been useful in determining the migration
speed of ovarian carcinoma cells, showing that the a-2 integrin
subunit is essential for migration (Kokenyesi et al, 2003). The role
of retinoic acid at inhibiting the migration of neuroblastoma cells
has also been described using this technique (Voigt and Zintl,
2003).
Similar results were obtained for both HBL and C8161 cells
irrespective of the method of assessment. Both cells were highly
responsive to TNF-a and the time course of action (18– 28 h) was
consistent with this cytokine causing an upregulation of integrin
subunits, which could be responsible for an increase in migration
(Zhu et al, 2002). The inhibitory effect of a neutralising antibody to
the b1 integrin subunit was consistent with this. The finding that
TNF-a increases the migration of melanoma cells is consistent with
and strongly supports an inflammatory environment promoting
melanoma metastases. In addition, a-MSH blocked the response to
TNF-a for the HBL melanoma cells but not the C8161 line, and is
therefore consistent with an anti-inflammatory action of this
molecule.
Melanocortin peptides interact with a family of melanocortin
receptors, MC-1R to MC-5R. The HBL and C8161 cells both
possess melanocortin type 1 and 2 receptors (Eves et al, 2003, in
press). However, the HBL cell line is wild type for MC-1R, while the
C8161 cell has a nonfunctional variant (Sanchez-Mas et al, 2002).
In this study, the HBL cells responded to a-MSH with a reduction
in migration, whereas the C8161 cells did not. However, when
C8161 cells were stably transfected with the wild-type MC-1
receptor, they responded to a-MSH with a significant reduction in
cell migration. Stable transfection of the C8161 melanoma cells
with the wild-type MC-1R and the restoration of an a-MSH
response provides strong evidence that this peptide is acting by the
MC-1R receptor to reduce cell migration. The dose–response
curve to a-MSH showed that relatively low concentrations were
capable of opposing TNF-a, whereas higher concentrations were
without effect. Our own group (Morandini et al, 1998; Hedley et al,
1998, 2000; Haycock et al, 1999a, b, 2000; Moustafa et al, 2002) and
others (Lipton and Catania, 1997) have shown previously that the
anti-inflammatory and anti-oxidative properties of a-MSH often
seem to be more effective at lower rather than higher concentra-
tions. It is not entirely known why this is observed, but we suspect
that dual signalling pathways from the melanocortin receptor
account for this. A long-standing problem in precisely dissecting
the mechanism of a-MSH action is the lack of neutralising
antibodies to the MC-1R receptor or a functional antagonist for a-
MSH.
In conclusion, we provide evidence that TNF-a has a dramatic
effect on migration of human cutaneous melanoma cells in vitro
and that a-MSH plays an important role in reducing cell migration
and opposing the promigratory effects of TNF-a. Furthermore, we
substantiate that the inhibitory action of a-MSH requires the
expression of a functional MC-1 receptor. We also show that the b1
integrin subunit is required for melanoma cell migration. The
study also provides a simple model for following cell migration,
which can be used to investigate new pharmaceutical approaches
for investigating melanoma invasion/migration.
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